In vitro biological activities of a combination of Ha-rak remedy, Piper betle, and Garcinia mangostana for the treatment of atopic dermatitis

Ha-rak 药物、槟榔和山竹的组合疗法治疗特应性皮炎的体外生物活性

阅读:1

Abstract

BACKGROUND AND PURPOSE: Ha-rak (HR), an equal-proportion combination of roots from Capparis micracantha DC., Clerodendrum petasites S. Moore., Ficus racemosa L., Harrisonia perforata (Blanco) Merr., and Tiliacora triandra (Colebr.) Diels, Piper betle L. (PB), and Garcinia mangostana L. (GM) are commonly used in traditional Thai medicine to treat skin diseases, including atopic dermatitis (AD). Combining three medicines in adjusted proportions can improve efficacy, reduce toxicity, and reduce medication. This study aimed to evaluate the anti-allergic, anti-inflammatory, antimicrobial, and cytotoxic activities of the ethanolic extracts of different combinations to analyze the relationship among elements, medicinal tastes, and biological activities. EXPERIMENTAL APPROACH: The biological activities (anti-allergic, anti-inflammatory, and anti-microbial activities and cell viability) of ethanolic extracts of plants and their combinations in various proportions were evaluated, as well as the chemical content of the developed remedies using the HPLC technique. FINDINGS/RESULTS: HMB-123 was the most significantly effective combination for AD. HMB-123 reduced β-hexosaminidase release from RBL-2H3 cells to a greater extent than chlorpheniramine. HMB-123 significantly inhibited nitric oxide and TNF-α production in LPS-stimulated RAW 264.7 cells. HMB-123 demonstrated antibacterial activity against all tested bacteria and antifungal activity against Candida albicans. For single extract, PB exhibited the highest anti-fungal activity, while GM exhibited the highest anti-bacterial activity. CONCLUSION AND IMPLICATIONS: The combined extracts showed potential as an optimized remedy for AD. HMB-123 demonstrated the highest anti-allergic, anti-inflammatory, and antimicrobial activities, making it a promising development candidate for AD treatment. To confirm safety and efficacy, further pre-clinical and clinical testing is necessary.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。